Once weekly prophylaxis with emicizumab leads to a significantly lower bleeding rate in people with severe haemophilia A without factor VIII inhibitors compared to no prophylaxis or previous treatment with factor VIII prophylaxis, a phase 3 trial has shown. A study of 152 patients from age 12 years extends an earlier efficacy and safety study ...
Novel bispecific antibody allows weekly prophylaxis for haemophilia A
By Mardi Chapman
30 Aug 2018